project . 2015 - 2020 . Closed

MoTriColor

Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor)
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 635342 Call for proposal: H2020-PHC-2014-two-stage
  • Funded under: H2020 | RIA Overall Budget: 4,948,740 EURFunder Contribution: 4,948,740 EUR
  • Status: Closed
  • Start Date
    01 Oct 2015
    End Date
    30 Nov 2020
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
Colorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease with distinct molecular subtypes. These subtypes have different biological processes at the basis of their disease and consequently their prognosis and responses to therapy are also different. We have previously developed molecular diagnostic assays using a single platform on routine FFPE tumour biopsies. These assays identify gene expression profiles with distinct prognosis and drug response phenotypes (CMS4/c-type, BRAF mutant-like, and MSI-like). Our overall objective is to develop targeted therapies more effective than the current therapies that do not take advantage of molec...
Description
Colorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease with distinct molecular subtypes. These subtypes have different biological processes at the basis of their disease and consequently their prognosis and responses to therapy are also different. We have previously developed molecular diagnostic assays using a single platform on routine FFPE tumour biopsies. These assays identify gene expression profiles with distinct prognosis and drug response phenotypes (CMS4/c-type, BRAF mutant-like, and MSI-like). Our overall objective is to develop targeted therapies more effective than the current therapies that do not take advantage of molec...
Any information missing or wrong?Report an Issue